Option chain shows key data for Ernexa Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Ernexa Therapeutics.

Ernexa Therapeutics (NASDAQ:ERNA) Stock, Option Chain

Eterna Therapeutics

Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.

Nvidia, Palantir, Clover Health, Joby Aviation, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATCH

ENVB

ERNA

FFIC

FRES

HAFC

HCWB

HSDT

INCY

NCNC

PRFX

QUBT

SOAR

TFFP

WAVE

ZENV

ZONE

Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket

Tesla Inc. TSLA

AEMD

APLM

AREN

CMAX

CYCN

FLYE

LAZR

LBRT

MNDR

NTLA

QMMM

SMCI

SYTA

TSLA

VVPR

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Biotech

Penny Stocks

Health Care

Market-Moving Exclusives

Exclusives

General

LCTX

Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ: 

EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics

Ernexa Therapeutics Inc

Press Releases

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

Management

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease

Ernexa Therapeutics Closes New Funding Round

Ainos

Aprea Therapeutics

BioCardia

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Curis

Ernexa Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

HCW Biologics

HOOKIPA Pharma

iBio

Imunon

Immuron Limited - American Depositary Shares

Immuron

Moleculin Biotech

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

PharmaCyte Biotech

Rallybio

SAB Biotherapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Spruce Biosciences

Synlogic

Turnstone Biologics

Comments

Ernexa Therapeutics

Ernexa Therapeutics (ERNA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga